ACTIMIS is a multinational, multicenter, randomized, double-blind, placebo-controlled, single-parallel, escalating dose phase 1b/2a safety and efficacy study of glenzocimab used as an add-on to standard of care therapy for acute ischemic stroke.
GARDEN is a randomized, double blind, multicenter, placebo-controlled, parallel group, exploratory efficacy and safety phase 2 study of glenzocimab in sars-cov-2-related acute respiratory distress syndrome (ARDS).
ACTISAVE is a randomized, double-blind, multicenter, multinational, placebo-controlled, parallel group, single dose, phase 2/3 adaptive efficacy and safety study of glenzocimab used as an add-on therapy on top of standard of care in the 4.5 hours following an acute ischemic stroke.
GREEN is a randomized, double-blind, multicenter, placebo-controlled, efficacy and safety phase 2/3 study of glenzocimab used as an add-on therapy on top of mechanical thrombectomy for acute ischemic stroke. The GREEN study is sponsored by Paris Public Hospitals (Assistance Publique – Hôpitaux de Paris) and is part of the RHU BOOSTER, receiving financial support from the French National Research Agency (Agence Nationale de la Recherche) and the Government’s Investments for the Future program (Programme Investissements d’Avenir).